09.09.20

Scottish Medicines Consortium Accepts Iluvien for Prevention of Relapse in Recurrent Noninfectious Uveitis

Source: Alimera Sciences

The Scottish Medicines Consortium (SMC) has accepted Iluvien (190µg fluocinolone acetonide (FAc) intravitreal implant in applicator) for use within NHS Scotland for prevention of relapse in recurrent noninfectious uveitis affecting the posterior segment of the eye (NIU-PS) in adults.1

NIU-PS is a sight threatening, inflammatory condition chiefly affecting people during prime working years. The treatment of NIU-PS can present substantial challenges, and the unpredictability of uveitis recurrence can make it difficult for patients to plan any aspect of their lives.2 

The SMC’s decision means there is now a treatment option available to patients in Scotland which greatly increases the time patients are free from the recurrence of uveitis (median 657 days recurrence-free for eyes treated with Iluvien compared with 70.5 days for eyes given treated control).4 Study data also shows that Iluvien prevents recurrence for up to 6 months in more than two thirds (72.4%) of eyes3 and for up to 3 years in a third (34.5%) of eyes.4 Additionally, patients treated with Iluvien required fewer adjunctive treatments (57.5%) compared to (97.6%) those receiving treated control.4

Iluvien delivers a continuous, sustained release of steroid at sub-microgram doses to the retina each day for up to 3 years, reducing ocular inflammation and minimizing the side effects associated with systemic steroids, whilst also lowering the need for the repeated injections required with local treatments.5,6

Following release of the SMC public notification, Iluvien will become funded and available immediately through the NHS to Scottish patients with recurrent NIU-PS.

“Iluvien becoming available for treatment of NIU-PS through the NHS in Scotland is incredibly welcome news. It is good to have a treatment option that can be directly delivered into the eye which helps keep inflammation down to non-sight threatening levels,” Dr. Mohan Varikkara, Consultant Ophthalmologist at University Hospital Ayr, said in a company news release. “It is a long acting implant which could potentially work for 3 years to prevent relapse and protect patients from further vision loss. The Iluvien implant can also reduce the need for systemic medications, minimizing their associated side effects and decreasing the need for regular blood monitoring, thus reducing the burden for patients.”

References:

  1. https://www.scottishmedicines.org.uk/medicines-advice/fluocinolone-acetonide-iluvien-full-smc2260/
  2. Yeh S., Shantha JG., The burden of noninfectious uveitis of the posterior segment: a review. Retina Today 2016; July/August: 47-51.
  3. ILUVIEN 190 micrograms intravitreal implant in applicator. Smpc information. https://www.medicines.org.uk/emc/product/3061  Last updated 28 March 2019. Accessed August 2019.
  4. Jaffe GJ, Pavesio CE; Study Investigators. Effect of a fluocinolone acetonide insert on recurrence rates in noninfectious intermediate, posterior, or panuveitis: Three-year results. Ophthalmology. 2020 [article in press].
  5. Jaffe GJ, Foster S, et al. Effect of an injectable Fluocinolone Acetonide insert on recurrence rates in chronic non-infectious uveitis affecting the posterior segment (12-month results). American Academy of Ophthalmology. 2016. ISSN 0161-6420/16.
  6. Larson T, Nussenblatt RB, Sen HN, et al. “Emerging drugs for uveitis”. Expert Opinion on Emerging Drugs. June 2011;16(2): 309–22.
  7. Barisani-Asenbauer T, Maca SM, Mejdoubi L, et al. Uveitis–a rare disease often associated with systemic diseases and infections–a systematic review of 2619 patients. Orphanet J Rare Dis. 2012;7:57.
  8. Jaffe GJ., Lin P., Keenan RT., et al. Effect of an injectable Fluocinolone Acetonide insert on recurrence rates in chronic non-infectious uveitis affecting the posterior segment (Two-year results). American Academy of Ophthalmology. 2018. ISSN 0161-6420/18.                                      

 

 

 

Related Content